TY - JOUR
T1 - Double-Negative T Cell Levels Correlate with Chronic Graft-versus-Host Disease Severity
AU - Moreau, Philippe
AU - Rajkumar, S. Vincent
AU - Mateos, Maria-Victoria
AU - Gay, Francesca
AU - Skacel, Tomas
AU - Schjesvold, Fredrik
AU - Chng, Wee Joo
AU - Hajek, Roman
AU - Zweegman, Sonja
AU - Min, Chang-Ki
AU - Dash, Ajeeta B
AU - Pluta, Agnieszka
AU - Iida, Shinsuke
AU - Labotka, Richard
AU - Teng, Zhaoyang
AU - Spencer, Andrew
AU - Kaiser, Martin
AU - Weisel, Katja Christina
AU - Dimopoulos, Meletios
AU - Beksac, Meral
AU - Suryanarayan, Kaveri
AU - Morgan, Gareth
AU - Maisnar, Vladimir
AU - Goldschmidt, Hartmut
N1 - Funding Information: Financial disclosure: This work was supported by grants from Fonds de la recherche en santé du Québec, the Maryse and William Brock Research Chair in Applied Research into Stem Cell Transplantation , the Cancer Research Society ( 16255, 21006, 22669, and 23189 ), and the Canadian Institutes for Health Research ( 159603 ). Conflict of interest statement: There are no conflicts of interest to report. Authorship statement: E.E.H. and S.T. contributed equally to this work. Publisher Copyright: © 2018 American Society for Blood and Marrow Transplantation Copyright: Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/1/1
Y1 - 2019/1/1
N2 - Chronic graft-versus-host disease (cGVHD) is a major complication, affecting 50% to 80% of long-term survivors of allogeneic hematopoietic stem cell transplantation. Current cGVHD therapies are neither specific nor curative, and patients are typically maintained for several months to years under immunosuppressive regimens that are associated with important side effects and increased susceptibility to life-threatening infections. As a result, continued investigation into the pathology of the disease and the search for novel diagnostic and therapeutic strategies to treat cGVHD remains a high priority. We report that the cellular dynamics of various immune cell subsets are related to cGVHD onset and severity in a cohort of allogeneic hematopoietic stem cell transplantation recipients. We document a decrease in the proportion of CD45RO + CD4 −CD8 − (double-negative [DN]) T cells at the onset of cGVHD, a time at which serum levels of B cell activating factor and B cells are increased. We also find that DN T cell levels are correlated with cGVHD severity. Our present findings are in line with the view that activated DN T cells exhibit their immunoregulatory potential by eliminating B cells in vivo. Taken together, these findings suggest that maintaining elevated DN T cell numbers before the onset of cGVHD may prevent pathological B cell responses.
AB - Chronic graft-versus-host disease (cGVHD) is a major complication, affecting 50% to 80% of long-term survivors of allogeneic hematopoietic stem cell transplantation. Current cGVHD therapies are neither specific nor curative, and patients are typically maintained for several months to years under immunosuppressive regimens that are associated with important side effects and increased susceptibility to life-threatening infections. As a result, continued investigation into the pathology of the disease and the search for novel diagnostic and therapeutic strategies to treat cGVHD remains a high priority. We report that the cellular dynamics of various immune cell subsets are related to cGVHD onset and severity in a cohort of allogeneic hematopoietic stem cell transplantation recipients. We document a decrease in the proportion of CD45RO + CD4 −CD8 − (double-negative [DN]) T cells at the onset of cGVHD, a time at which serum levels of B cell activating factor and B cells are increased. We also find that DN T cell levels are correlated with cGVHD severity. Our present findings are in line with the view that activated DN T cells exhibit their immunoregulatory potential by eliminating B cells in vivo. Taken together, these findings suggest that maintaining elevated DN T cell numbers before the onset of cGVHD may prevent pathological B cell responses.
KW - B cells
KW - BAFF
KW - DN T cells
KW - chronic graft vs host disease immunoregulatory cells
UR - http://www.scopus.com/inward/record.url?scp=85055270924&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.bbmt.2018.09.008
DO - https://doi.org/10.1016/j.bbmt.2018.09.008
M3 - Article
SN - 1083-8791
VL - 25
SP - 19
EP - 25
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 1
ER -